Case Studies in the Management of Metastatic Breast Cancer with Eribulin

Case Studies in the Management of Metastatic Breast Cancer with Eribulin

Show other versions (1)

Bibliographic Details
Main Authors:	Sharon Wilks, Kristi McIntyre
Format:	Article
Language:	English
Published:	SAGE Publishing 2015-10-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	http://www.la-press.com/case-studies-in-the-management-of-metastatic-breast-cancer-with-eribul-article-a5137

Similar Items

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
by: Sharon Wilks, et al.
Published: (2015-01-01)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
by: Lee Schwartzberg, et al.
Published: (2019-06-01)

Eribulin mesylate in the treatment of metastatic breast cancer
by: Jain S, et al.
Published: (2012-01-01)

Budget impact of eribulin in metastatic breast cancer in Russian Federation
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
by: Doherty MK, et al.
Published: (2015-01-01)

A Retrospective Evaluation of Eribulin Dosing Schedules in Metastatic Breast Cancer
by: Gagliardo, Camille, et al.
Published: (2016)

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.
by: Natsuko Satomi-Tsushita, et al.
Published: (2019-01-01)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
by: Renaud Sabatier, et al.
Published: (2021-03-01)

Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer
by: Diana Donovan, et al.
Published: (2014-01-01)

Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer
by: Diana Donovan, et al.
Published: (2014-05-01)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
by: Mu&ntilde;oz-Couselo E, et al.
Published: (2011-11-01)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
by: Doherty MK, et al.
Published: (2015-04-01)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
by: Tremblay G, et al.
Published: (2016-09-01)

Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients
by: Ditsatham C, et al.
Published: (2018-07-01)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
by: Tanya E. Keenan, et al.
Published: (2021-09-01)

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
by: Jean-David Fumet, et al.
Published: (2018-08-01)

Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
by: Shinichiro Kashiwagi, et al.
Published: (2017-08-01)

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
by: Twelves C, et al.
Published: (2011-08-01)

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
by: Yu-Ju Lin, et al.
Published: (2021-06-01)

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
by: Gabriel Tremblay, et al.

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings
by: Victor C. Kok
Published: (2015-01-01)

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings
by: Victor C. Kok
Published: (2015-12-01)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
by: Jin Sun Lee, et al.
Published: (2019-11-01)

Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01)

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
by: Yannan Zhao, et al.
Published: (2021-07-01)

The improvement in overall survival for patients with metastatic breast cancer treated with eribulin: the resolution based on results of the expert council
by: V S Andrianova, et al.
Published: (2015-03-01)

Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial
by: F Sh Ahmetzanov, et al.
Published: (2014-09-01)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
by: Mikihiro Yoshie, et al.
Published: (2021-08-01)

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
by: Vincenzo Adamo, et al.
Published: (2019-12-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
by: BJ Srinivasa, et al.
Published: (2018-06-01)

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
by: L V Bolotina, et al.
Published: (2016-09-01)

Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series
by: Alex Y. Chang, et al.
Published: (2015-05-01)

Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series
by: Alex Y. Chang, et al.
Published: (2015-01-01)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
by: Wataru Goto, et al.
Published: (2020-12-01)

Methyl Sulfone Blocked Multiple Hypoxia- and Non-Hypoxia-Induced Metastatic Targets in Breast Cancer Cells and Melanoma Cells.
by: Joan McIntyre Caron, et al.
Published: (2015-01-01)

Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study
by: Ornella Garrone, et al.
Published: (2020-10-01)

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
by: Qi Zhao, et al.
Published: (2021-06-01)